Spots Global Cancer Trial Database for Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC

Official Title: Progression Survival Time According to Time-of-Day (ToD) of Administration of Immunochemotherapy for Advanced Non-small Cell Lung Cancer: A Phase III Randomized Control Trial

Study ID: NCT05549037

Conditions

Non-small Cell Lung Cancer

Interventions

Pembrolizumab, Sintilimab

Study Description

Brief Summary: This study aims to explore time-of-day of administration of immunochemotherapy on the efficacy for treatment naive advanced non-small cell lung cancer.

Detailed Description: All the advanced NSCLC patients who were treated with chemotherapy plus pembrolizumab or sitilimab will be randomized to two groups. One for morning group, the patients in this group were treated with chemotherapy plus pembrolizumab or sintilimab before 15:00. One for afternoon group, the patients in this group were treated with chemotherapy plus pembrolizumab or sintilimab after 15:00.